Sunflower Pharmaceutical Group Co.,Ltd

Shenzhen Stock Exchange 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd EBIT Margin for the year ending December 31, 2023: 23.96%

Sunflower Pharmaceutical Group Co.,Ltd EBIT Margin is 23.96% for the year ending December 31, 2023, a 11.71% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Sunflower Pharmaceutical Group Co.,Ltd EBIT Margin for the year ending December 31, 2022 was 21.45%, a 5.62% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd EBIT Margin for the year ending December 31, 2021 was 20.30%, a -9.02% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd EBIT Margin for the year ending December 31, 2020 was 22.32%, a 23.43% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd EBIT Margin for the year ending December 31, 2019 was 18.08%, a 11.14% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Shenzhen Stock Exchange: 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd

CEO	Ms. Yi Guan
IPO Date	Dec. 30, 2014
Location	China
Headquarters	Concentrated Area, Yingbin Road
Employees	5,776
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sunflower Pharmaceutical Group Co.,Ltd researches, develops, manufactures, and markets Chinese patent medicines in China. The company also produces chemical, biological, and health care medicines. Its products are used in therapeutic areas, such as pediatrics, gynecology, digestive system, respiratory and cold, rheumatism and bone disease, and cardiovascular and cerebrovascular. The company sells its products under the Sunflower and Little Sunflower brands. Sunflower Pharmaceutical Group Co.,Ltd was founded in 2005 and is based in Harbin, China.

Key trends

Past 5 years